NCT04895631 is a Phase 3 clinical trial of 18F-Fluorocholine in Hyperparathyroidism, Primary, sponsored by Thomas Hope.

Who is sponsoring NCT04895631?

NCT04895631 is sponsored by Thomas Hope.

What condition does NCT04895631 study?

NCT04895631 studies Hyperparathyroidism, Primary.

Is NCT04895631 still recruiting?

NCT04895631 is currently recruiting now. Last updated 30 December 2024.

Last reviewed 2024-12-30 · How we verify

NCT04895631

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

Recruiting now Phase 3 Last updated 30 December 2024

What this trial tests

Phase 3 trial testing 18F-Fluorocholine in Hyperparathyroidism, Primary in 140 participants. Currently enrolling.

Timeline

30 June 2021

Primary endpoint
30 June 2026

30 June 2027

Quick facts

Lead sponsor	Thomas Hope
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	140
Start date	30 June 2021
Primary completion	30 June 2026
Estimated completion	30 June 2027
Sites	1 location across United States

Drugs / interventions tested

18F-Fluorocholine
Positron emission tomography (PET) — full drug profile →

Conditions studied

Hyperparathyroidism, Primary — all drugs for Hyperparathyroidism, Primary →

Sponsor

Thomas Hope — full company profile →

Who can join

13 and older, any sex, with Hyperparathyroidism, Primary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective single arm single center Phase III study evaluating the ability of 18F-fluorocholine to detect the location of parathyroid adenomas.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pathways and challenges in the clinical translational of radiopharmaceuticals for pediatric investigations.
Stauff E, Karimi H, Kecskemethy HH, Shaffer TH, et al · · 2025 · PMID 41282032 · DOI 10.3389/fmed.2025.1658588

Verify or expand the search:

Other trials of 18F-Fluorocholine

Trials testing the same drug.

NCT03764007 — 18F-Fluorocholine for the Detection of Parathyroid Adenomas · Phase 2, PHASE3 · completed

Other recruiting trials for Hyperparathyroidism, Primary

Currently open trials in the same condition.

NCT06562881 — Patient Navigation to Improve Surgical Access in Primary Hyperparathyroidism · NA · recruiting

Other Thomas Hope trials

Trials by the same sponsor.

NCT07052760 — Imaging of Solid Tumors Using DLL3 SPECT · EARLY_PHASE1 · not yet recruiting
NCT06961084 — Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer · Phase 2 · recruiting
NCT07054346 — Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 · Phase 1 · recruiting
NCT06474533 — Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm · recruiting
NCT05180162 — Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04895631 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Thomas Hope
Last refreshed: 30 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04895631.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing